- Home
- CRBU vs ACRV Comparison
CRBU vs ACRV Comparison
Compare CRBU & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- ACRV
- Stock Information
- Founded
- CRBU 2011
- ACRV 2018
- Country
- CRBU United States
- ACRV United States
- Employees
- CRBU N/A
- ACRV N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- CRBU Health Care
- ACRV Health Care
- Exchange
- CRBU Nasdaq
- ACRV Nasdaq
- Market Cap
- CRBU 151.2M
- ACRV 170.3M
- IPO Year
- CRBU 2021
- ACRV 2022
- Fundamental
- Price
- CRBU $1.52
- ACRV $5.65
- Analyst Decision
- CRBU Strong Buy
- ACRV Strong Buy
- Analyst Count
- CRBU 5
- ACRV 5
- Target Price
- CRBU $11.80
- ACRV $22.40
- AVG Volume (30 Days)
- CRBU 1.6M
- ACRV 50.9K
- Earning Date
- CRBU 03-10-2025
- ACRV 11-13-2024
- Dividend Yield
- CRBU N/A
- ACRV N/A
- EPS Growth
- CRBU N/A
- ACRV N/A
- EPS
- CRBU N/A
- ACRV N/A
- Revenue
- CRBU $11,475,000.00
- ACRV N/A
- Revenue This Year
- CRBU N/A
- ACRV N/A
- Revenue Next Year
- CRBU N/A
- ACRV N/A
- P/E Ratio
- CRBU N/A
- ACRV N/A
- Revenue Growth
- CRBU N/A
- ACRV N/A
- 52 Week Low
- CRBU $1.50
- ACRV $3.19
- 52 Week High
- CRBU $8.33
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- CRBU 34.82
- ACRV 41.71
- Support Level
- CRBU $1.50
- ACRV $5.36
- Resistance Level
- CRBU $1.69
- ACRV $6.00
- Average True Range (ATR)
- CRBU 0.13
- ACRV 0.52
- MACD
- CRBU -0.01
- ACRV -0.01
- Stochastic Oscillator
- CRBU 3.70
- ACRV 17.74
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.